Biomedical Research News

Gerstner Philanthropies proudly celebrates the 20th anniversary of the Broad Institute of MIT and Harvard, honoring two decades of groundbreaking biomedical and genomic research. Since its founding in 2004 following the completion of the Human Genome Project, the Broad Institute has made monumental advances in disease understanding and medical innovation. Our partnership with Broad, established over a decade ago, includes Louis V. Gerstner, Jr.'s leadership as Board Chairman from 2013-2021, and the 2019 founding of the Gerstner Center for Cancer Diagnostics. The Gerstner Center for Cancer Diagnostics aims to advance blood-based biopsies and other technologies to speed cancer diagnoses and track patients' response to therapies.

Renhe Luo, PhD, who recently graduated from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), has been awarded the 2024 Chairman’s Prize. The competitive award is presented annually and was established by GSK’s Board of Trustees Chair Emeritus Louis V. Gerstner Jr., for whom the school is named. This year’s $2,000 Chairman’s Prize was awarded to Dr. Luo for his research on gene enhancers, which are regulatory DNA sequences that are critical in determining when and where genes are turned on or off. Enhancers play an important role in development, cell differentiation, and the response to environmental signals. “This research provides strategies for discovering more comprehensive enhancer sets, both in normal development and in cells transitioning to cancer cells or other disease cells,” Dr. Luo says.

Memorial Sloan Kettering Cancer Center (MSK) held its Academic Convocation and Commencement on May 15, 2024, celebrating new graduates and award winners. Our Chairman, Louis V. Gerstner, Jr., namesake of the Gerstner Sloan Kettering Graduate School, had the opportunity to honor the graduates. This year, 10 students earned their doctoral degrees in cancer biology from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK). In addition, five practicing MSK doctors received Master of Science degrees in clinical and translational cancer research from GSK. Keynote speaker Elaine Fuchs, PhD, received an honorary degree for her contributions to science. Congratulations to all the graduates on their achievements!

Scientists from the Gerstner Center for Cancer Diagnostics at the Broad Institute and their colleagues at MIT have developed two agents that could one day be given to patients shortly before a blood draw to allow physicians to better detect tumor DNA using liquid biopsy. Liquid biopsies have the potential to transform how cancers are diagnosed, monitored, and treated by detecting DNA that tumors shed into the blood, but the body presents a significant challenge. Immune cells in the liver and DNA-degrading enzymes in blood remove circulating tumor DNA from the bloodstream within minutes, making this DNA difficult to capture and detect in a blood test. Now, researchers at MIT and the Broad Institute have developed injectable "priming agents" that enhance liquid biopsy accuracy. These agents, using nanoparticles and antibodies, significantly increase the detection of circulating tumor DNA (ctDNA) in the bloodstream. In mouse trials, these agents boosted ctDNA by over 10 times, improving the detection rate from below 10% to over 75%. This breakthrough could not only transform cancer diagnostics but also holds promise for other health areas. Director of the Gerstner Center for Cancer Diagnostics, Viktor Adalsteinsson shared “Boosting circulating tumor DNA in blood is just the tip of the iceberg… Priming is a new frontier we’re excited to further develop in cancer diagnostics and beyond.”

Gerstner Philanthropies has committed an additional $20 million to the Gerstner Center for Cancer Diagnostics at the Broad Institute. This commitment will support the development and optimization of liquid biopsy technology to enable more precise cancer care for millions worldwide. Directed by Dr. Viktor Adalsteinsson, this technology allows physicians to detect cancer cells and cancer recurrence, earlier than ever before. “We always knew that detecting cancer recurrence with a blood test would be an incredible feat, and the scientists in the Gerstner Center have risen to the challenge," said Todd Golub, director of the Broad Institute. This development for early detection is key to measuring patients’ response and assessing treatment options. “I first partnered with the Broad to launch the Gerstner Center in order to impact clinical care for cancer patients, and I’ve been pleased to see that Viktor and his team have created an engine of innovation that could transform not only cancer treatment but possibly other fields as well,” said Gerstner.